(Reuters) - AstraZeneca declined to comment on the pending acquisition, which was first reported by the Wall Street Journal. The paper said on its Web site the deal could be worth more than $13 billion.
Read more at Reuters.com Business News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment